SCHEMBL19343573

SCHEMBL19343573

CC(=O)NC1(c2cccc(Br)c2)CCCN(Cc2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A9 P48067 1/20 0.50
▸ CYP2D6 P10635 5/20 0.48
▸ ALDH1A1 P00352 3/20 0.46
▸ TSHR P16473 2/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CHRM2 P08172 2/20 0.44
▸ CHRM1 P11229 2/20 0.44
▸ CHRM3 P20309 2/20 0.44
▸ CXCR3 P49682 2/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ SIGMAR1 Q99720 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ CYP2C19 P33261 1/20 0.42
▸ FAAH O00519 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19343289 0.88 CYP2D6 (0.51) SLC6A9CYP2D6ALDH1A1TSHRCYP3A4
SCHEMBL23862834 0.82 SLC6A9 (0.43) SLC6A9CYP2D6ALDH1A1TSHRCYP3A4
SCHEMBL19331129 0.82 POLB (0.57) SLC6A9CYP2D6ALDH1A1TSHRCYP3A4
SCHEMBL19331105 0.81 POLB (0.52) CYP2D6ALDH1A1TSHRCYP3A4CHRM2
SCHEMBL23366366 0.80 SMN1; SMN2 (0.42) SLC6A9CYP2D6ALDH1A1TSHRCYP3A4
SCHEMBL19331263 0.79 PHGDH (0.50) SLC6A9CYP2D6ALDH1A1KDM4E
SCHEMBL19330808 0.78 KDM4E (0.56) CYP2D6ALDH1A1CHRM2CHRM1CHRM3
SCHEMBL19330992 0.78 SMN1; SMN2 (0.49) CYP2D6TSHRCYP3A4CHRM2CHRM1
SCHEMBL2878982 0.76 SLC6A9 (0.51) SLC6A9CYP2D6ALDH1A1TSHRCYP3A4
SCHEMBL7502902 0.75 CYP2D6 (0.58) CYP2D6ALDH1A1TSHRCYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3884939-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
EP-3884939-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 — — US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 — — US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 — — US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 — — US disclosed
EP-3884939-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2021-09-29 — — EP disclosed
EP-3884939-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2021-09-29 — — EP disclosed
EP-3426243-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2021-05-19 — — EP disclosed
EP-3426243-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2021-05-19 — — EP disclosed
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-03-23 — — US disclosed
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-03-23 — — US disclosed
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 — — US disclosed
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 — — US disclosed
WO-2017156165-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD SLC6A9 1886/4885CYP2D6 1356/4885ALDH1A1 222/4885
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD SLC6A9 1886/4885CYP2D6 1356/4885ALDH1A1 222/4885
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD SLC6A9 1886/4885CYP2D6 1356/4885ALDH1A1 222/4885
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD SLC6A9 1886/4885CYP2D6 1356/4885ALDH1A1 222/4885
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD SLC6A9 1886/4885CYP2D6 1356/4885ALDH1A1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback